Co-targeting of Adenosine Signaling Pathways for Immunotherapy: Potentiation by Fc Receptor Engagement

Rony Dahan; Jeffrey V. Ravetch

doi:10.1016/j.ccell.2016.08.007

Co-targeting of Adenosine Signaling Pathways for Immunotherapy: Potentiation by Fc Receptor Engagement

Rony Dahan, Jeffrey V. Ravetch

Research output: Contribution to journal › Short survey › peer-review

Abstract

Targeting the signaling pathway of the immunosuppressive metabolite adenosine is an emerging approach for cancer immunotherapy. In this issue of Cancer Cell, Young et al. describe that co-inhibition of the adenosingenic pathway through blockade of both CD73 and A2AR enhances antitumor efficacy through distinct mechanisms.

Original language	English
Pages (from-to)	369-371
Number of pages	3
Journal	Cancer Cell
Volume	30
Issue number	3
DOIs	https://doi.org/10.1016/j.ccell.2016.08.007
State	Published - 12 Sep 2016
Externally published	Yes

All Science Journal Classification (ASJC) codes

Oncology
Cell Biology
Cancer Research

Access to Document

10.1016/j.ccell.2016.08.007

Cite this

@article{d6d05aa9072e413c9d926f94f25d88d5,

title = "Co-targeting of Adenosine Signaling Pathways for Immunotherapy: Potentiation by Fc Receptor Engagement",

abstract = "Targeting the signaling pathway of the immunosuppressive metabolite adenosine is an emerging approach for cancer immunotherapy. In this issue of Cancer Cell, Young et al. describe that co-inhibition of the adenosingenic pathway through blockade of both CD73 and A2AR enhances antitumor efficacy through distinct mechanisms.",

author = "Rony Dahan and Ravetch, \{Jeffrey V.\}",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",

year = "2016",

month = sep,

day = "12",

doi = "10.1016/j.ccell.2016.08.007",

language = "الإنجليزيّة",

volume = "30",

pages = "369--371",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "3",

}

TY - JOUR

T1 - Co-targeting of Adenosine Signaling Pathways for Immunotherapy

T2 - Potentiation by Fc Receptor Engagement

AU - Dahan, Rony

AU - Ravetch, Jeffrey V.

PY - 2016/9/12

Y1 - 2016/9/12

N2 - Targeting the signaling pathway of the immunosuppressive metabolite adenosine is an emerging approach for cancer immunotherapy. In this issue of Cancer Cell, Young et al. describe that co-inhibition of the adenosingenic pathway through blockade of both CD73 and A2AR enhances antitumor efficacy through distinct mechanisms.

AB - Targeting the signaling pathway of the immunosuppressive metabolite adenosine is an emerging approach for cancer immunotherapy. In this issue of Cancer Cell, Young et al. describe that co-inhibition of the adenosingenic pathway through blockade of both CD73 and A2AR enhances antitumor efficacy through distinct mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=84995685172&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2016.08.007

DO - 10.1016/j.ccell.2016.08.007

M3 - عرض مختصر

SN - 1535-6108

VL - 30

SP - 369

EP - 371

JO - Cancer Cell

JF - Cancer Cell

IS - 3

ER -

Co-targeting of Adenosine Signaling Pathways for Immunotherapy: Potentiation by Fc Receptor Engagement

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this